[7/28]
WHO ±Û·Î¹ú COVID-19 ¿ªÇÐ µ¿Çâ
(COVID-19 Global Epidemiological Update )
Coronavirus Disease 2019 (COVID-19) µ¿Çâ Highlights
ÁÖ¿ä ±¹°¡º° COVID-19 È®ÁøÀÚ, Ä¡¸í·ü ¹× ¿ÏÄ¡À²(2020.0728)
COVID-19 ±¹¿Ü¹ß»ýÇöȲÀº Áö¿ªº°·Î ¾Æ½Ã¾ÆÁö¿ª 29°³±¹, Áßµ¿Áö¿ª 18°³±¹, ¾Æ¸Þ¸®Ä«Áö¿ª 35°³±¹, À¯·´Áö¿ª 49°³±¹, ¿À¼¼¾Æ´Ï¾ÆÁö¿ª 4°³±¹, ¾ÆÇÁ¸®Ä«Áö¿ª 49°³±¹, ±×¿Ü ±âŸÁö¿ª Æ÷ÇÔÇÏ¿© Àü¼¼°èÀûÀ¸·Î È®ÁøÀÚ´Â 16,114,449¸í(½Å±Ô254,274¸í), »ç¸ÁÀÚ 646,641¸í(½Å±Ô 5,490¸í)À¸·Î º¸°íµÇ¾ú´Ù(2020³â7¿ù28ÀÏ ±âÁØ).
Ç¥ 1 ) COVID-19ÁÖ¿ä ¹ß»ý±¹°¡ µ¿Çâ(´©Àû¹ß»ý 20¸¸ ÀÌ»ó ±¹°¡)
Ãâó : Á߾ӹ濪´ëÃ¥º»ºÎ Á¤·Êºê¸®ÇÎÀÚ·á
Ç¥2) ÁÖ¿ä ±¹°¡ °ËÁø±º¼ö ¹× È®Áø·ü ºñ±³(2020³â 7¿ù 27ÀÏ ±âÁØ)
±¹°¡
|
°Ë»ç°Ç¼ö
|
È®ÁøÀÚ
|
°Ç¼ö´ëºñ È®Áø·ü
|
Áß±¹
|
N/A
|
83,891¸í
|
N/A
|
Çѱ¹
|
1,526,974°Ç
|
14,175¸í
|
0.9 %
|
ÀÌÅ»¸®¾Æ
|
N/A
|
246,118¸í
|
N/A
|
À̶õ
|
N/A
|
291,172¸í
|
N/A
|
ÀϺ»
|
720,501°Ç
|
29,989¸í
|
4.2 %
|
¹Ì±¹
|
N/A
|
4,234,140¸í
|
N/A
|
¿µ±¹
|
14,794,369°Ç
|
299,426¸í
|
2.0 %
|
* N/AÇ¥½Ã´Â ¹ÌÁý°è¸¦ ÀǹÌÇÔ
Ç¥3) ¼¼°èº¸°Ç±â±¸(WHO) Áö¿ªº° COVID-10 È®ÁøÀÚ, Ä¡¸í·ü (WHO Áö¿ªº° º¸°í-189È£)
Globally ÃÑ È®ÁøÀÚ16,114,449¸í(½Å±Ô254,274¸í), »ç¸ÁÀÚ 646,641¸í(½Å±Ô 5,490¸í)
±¸ºÐ
|
¾ÆÇÁ¸®Ä«
|
¾Æ¸Þ¸®Ä«
|
µ¿ºÎÁöÁßÇØ
|
À¯·´
|
µ¿³²¾Æ½Ã¾Æ
|
¼ÅÂÆò¾ç
|
È®ÁøÀÚ(¸í)
|
712,920
|
8,610,134
|
1,482,315
|
3,234,043
|
1,786,145
|
288,151
|
»ç¸ÁÀÚ(¸í)
|
11,900
|
337,439
|
37,932
|
210,518
|
40,615
|
8,224
|
Ä¡¸í·ü(CFR)
|
1.67%
|
3.92%
|
2.56%
|
6.51%
|
2.27%
|
2.84%
|
±×¸² 1) COVID-19 È®Áø ±¹°¡ ¹× Áö¿ªº° È®Áø »ç·Ê(2020³â7¿ù28ÀÏÀÚ WHO º¸°í)
Source: WHO Coronavirus disease 2019 (COVID-19) Situation Report -189 [¹Ù·Î°¡±â]
Ç¥ 4) ±¹°¡ ¹× Áö¿ªº° COVID-19 È®Áø ÇöȲ(2020³â7¿ù 28ÀÏÀÚ WHO º¸°í)
Source: WHO Coronavirus disease 2019 (COVID-19) Situation Report 189
±×¸² 3) COVID-19 È®Áø ¿ªÇа(³¯Â¥º°, Áö¿ªº° 2020³â 7¿ù28ÀÏÀÚ)
Source: WHO Coronavirus disease 2019 (COVID-19) Situation Report 189 [»ó¼¼º¸±â]
[ÃֽŠ¿¬±¸µ¿Çâ] Coronavirus 2019 (COVID-19)] Highlights
COVID-19 ȯÀÚ °øº¹Ç÷´ç(FBG)Àº »ç¸Á·ü ¿¹ÃøÁöÇ¥
Fasting blood glucose at admission is an independent predictor for 28-day mortality in patients with COVID-19 without previous diagnosis of diabetes: a multi-centre retrospective study
ÃֽŠ7¿ùÈ£ À¯·´ ´ç´¢º´ÇÐȸÁö Diabetologia, EASD (European Association for Study of Diabetes) ¹ßÇ¥¿¡ ÀÇÇϸé, COVID-19 °¨¿°À¸·Î ÀÎÇØ ÀÔ¿øÇÑ È¯ÀÚÀÇ ÀÔ¿ø ½Ã¿¡ ÃøÁ¤ÇÑ °øº¹ Ç÷´ç(FBG)Àº COVID-19 ¿¹ÈÄ¿¡ ´ëÇÑ Áõ»ó ¾ÇȻӸ¸ ¾Æ´Ï¶ó, 28ÀÏ »ç¸ÁÀ²( 28-day mortality)À» ¿¹ÃøÇÒ ¼ö ÀÖ´Â ÁöÇ¥°¡ µÈ´Ù´Â ¿¬±¸ °á°ú¸¦ º¸°íÇß´Ù. [»ó¼¼º¸±â]
COVID-19 ¸é¿ª¹ÝÀÀ -- Ç×ü 2°³¿ù°£ ¾ÈÁ¤ÀûÀ¸·Î Áö¼Ó
(COVID-19 immune response may remain stable for two months after diagnosis)
¿µ±¹ ·±´ø ¼¼ÀÎÆ® Á¶Áö ´ëÇаú º´¿ø(St George's, University of London & St George's University Hospitals NHS Foundation Trust)°ú ¸®¹öÇ® ÀÇÇÐ ¿¬±¸ÆÀ(Liverpool School of Tropical Medicine, Mologic Ltd. and Institut Pasteur de Dakar, Sénégal)ÀÌ Äڷγª-19 È®ÁøÀÚ 177¸íÀ» ´ë»óÀ¸·Î ÁøÇàÇÑ Ç×ü°Ë»ç °á°ú, COVID-19 °¨¿° Áø´Ü ÈÄ °ÅÀÇ 2 °³¿ùÀÌ Áö³ª¼ °¨¿°µÈ »ó´ç ¼öÀÇ È¯ÀÚÇ÷¾×¿¡¼ Ç×ü°¡ ¾ÈÁ¤ÀûÀ¸·Î À¯ÁöµÈ´Ù´Â º¸°í°¡ ¹ßÇ¥µÇ¾ú´Ù. [»ó¼¼º¸±â]
[NEJM Ãֽŵ¿Çâ] COVID-19 ÈæÀΰú ¹éÀÎȯÀÚÀÇ ÀÔ¿øÀ²°ú »ç¸Á·ü ºñ±³
Hospitalization and Mortality among Black Patients and White Patients with Covid-19
·çÀÌÁö¾Ö³ªÁÖÀÇ ´ë±Ô¸ð ÄÚȣƮ¿¬±¸¸¦ ÅëÇÏ¿© Covid-19·Î ÀÔ¿ø ÇÑ È¯ÀÚÀÇ 76.9 %¿Í »ç¸Á ȯÀÚÀÇ 70.6 %´Â ÈæÀÎÀ¸·Î ³ªÅ¸³µÀ¸³ª, ÀÔ¿ø ½Ã »çȸÀα¸ Åë°èÇÐÀû ¹× ÀÓ»óƯ¼ºÀÇ Â÷À̸¦ Á¶Á¤ÇÑ ÈÄ, ÈæÀÎ ÀÎÁ¾Àº ¹éÀÎ ÀÎÁ¾º¸´Ù º´¿ø ³» »ç¸Á·üÀÌ ³ôÁö ¾ÊÀ½À¸·Î ³ªÅ¸³µ´Ù. [»ó¼¼º¸±â]
NIH- Remdesivir (·½µ¥½Ãºñ¸£) COVID-19 Ä¡·áÁ¦·Î ½ÂÀÎ
¹Ì±¹ ±¹¸³º¸°Ç¿¬±¸¿ø(NIH)ÀÌ ¼öÇàÇÑ Ç×¹ÙÀÌ·¯½º ·½µ¥½Ãºñ¾î(remdesivir) ÀÓ»ó½ÃÇ迬±¸ °á°ú°¡ NEJM (New England Journal of Medicine.)À» ÅëÇØ ¹ßÇ¥µÇ¾ú´Ù. (https://www.nejm.org/doi/full/10.1056/NEJMoa2007764?query=featured_home)
ÀÌ °á°ú¸¦ ±Ù°Å·Î 5¿ù 1ÀÏ¿¡ ¹Ì±¹ FDA(½Ä¾àó)´Â ·½µ¥½Ãºñ¾î¸¦ ¡¸ÁßÁõ¡¹È¯ÀÚ(»ê¼ÒÆ÷ȵµ <94%, »ê¼Ò Ä¡·á ÇÊ¿ä)¿¡°Ô ±ä±Þ»ç¿ëÇã°¡¸¦ ½ÂÀÎÇÏ¿´À¸¸ç, ÀÌÁ¦ ·½µ¥½Ãºñ¾î°¡ COVID-19ÀÇ Ç¥ÁØ Ä¡·áÁ¦·Î »ç¿ëÇã°¡µÇ¾ú´Ù. [»ó¼¼º¸±â]
[±¹³»Ç÷ÀåÄ¡·á¼º°ø] COVID-19: ¿ÏÄ¡ÀÚ Ç÷ÀåÄ¡·á(Convalescent Plasma)
±¹³» ¼¼ºê¶õ½ºº´¿ø ¿¬±¸ÆÀÀº ¿ÏÄ¡ÀÚ Ç÷Àå(Convalescent Plasma) Ä¡·á¹æ¹ýÀ¸·Î ÀÓ»ó¿¡¼ Coronavirus disease 2019 (COVID-19)ÀÇ ¿ÏÄ¡ »ç·Ê¸¦ º¸°íÇß´Ù. ÀÌ°ÍÀº Çѱ¹¿¡¼ COVID-19¿¡ ´ëÇÑ ¿ÏÄ¡ÀÚ Ç÷Àå Ä¡·á¿¡ ´ëÇÑ Ã¹ ¹ø° ÀÓ»ó ¿ÏÄ¡»ç·ÊÀÌ´Ù. [»ó¼¼º¸±â]
COVID-19 Ä¡·áÁ¦°³¹ß ±Û·Î¹ú Àӻ󿬱¸ ÇÁ·ÎÁ§Æ®ÇöȲ
½ÅÁ¾ Äڷγª¹ÙÀÌ·¯½º °¨¿°Áõ(Äڷγª19) Ä¡·áÁ¦ °³¹ßÀ» À§ÇØ Àü¼¼°è°¡ ³ë·ÂÇÏ°í ÀÖ´Â °¡¿îµ¥, ÇöÀç Äڷγª 19 Ä¡·áÁ¦ °³¹ß°ú °ü·Ã ±¹Á¦ÀûÀ¸·Î Àӻ󿬱¸°¡ 335,815°ÇÀÌ ÁøÇà Áß¿¡ ÀÖ´Ù(2020³â 4¿ù 13ÀÏÀÚ µî·ÏÇöȲ). ¹Ì±¹ ±¹¸³º¸°Ç¿ø NIH ClinicalTrials.gov¿¡ µî·ÏµÇ¾î ÁøÇàÇÏ°í ÀÖ´Â COVID-19 °ü·Ã Àӻ󿬱¸´Â 300¿©°Ç ÀÌ»óÀÌ ÁøÇà Áß¿¡ ÀÖÀ¸¸ç, ¼¼°èº¸°Ç±â±¸(WHO)±¹Á¦Àӻ󿬱¸µî·Ï Ç÷§Æû(World Health Organization's International Clinical Trials Registry Platform, WHO ICTRP)¿¡¼´Â 590°ÇÀÇ ÇÁ·ÎÁ§Æ®°¡ ÇöÀç Àӻ󿬱¸ Áß¿¡ ÀÖ´Ù. [»ó¼¼º¸±â]
NEJM COVID-19 º¸°í [½ÉÇ÷°üÁúȯ ¾à¹°Ä¡·á, »ç¸Á·ü ¿äÀÎ ¿¬±¸(Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19): Angiotensin-converting–enzyme (ACE) inhibitors & angiotensin-receptor blockers (ARBs)]
º» ¿¬±¸´Â The New England Journal of Medicine 2020³â 5¿ù 1ÀÏÀÚ ¹ßÇ¥µÈ COVID-19 ½ÉÇ÷°üÁúȯÀÇ ¾à¹°Ä¡·á- Angiotensin-converting–enzyme (ACE) inhibitors¿Í Angiotensin-receptor blockers (ARBs) »ç¿ë¿¡ ´ëÇÑ ÀáÀçÀû À§Çؼº Æò°¡¿Í »ç¸Á·ü °ü·Ã¿äÀÎ ¿¬±¸ÀÌ´Ù.
º´¿ø ³» »ç¸ÁÀ² Áõ°¡¿Í °ü·ÃÀÖ´Â µ¶¸³¿äÀεéÀº ¾Æ·¡¿Í °°´Ù.
1. 65¼¼ ÀÌ»ó ¿¬·É( (mortality of 10.0%, vs. 4.9% among those ≤65 years of age; odds ratio, 1.93; 95% confidence interval [CI], 1.60 to 2.41) (65 ¼¼ ¹Ì¸¸ÀÇ »ç¸Á·üÀº 10.0 %, »ç¸Á·üÀº 4.9 %)
2. °ü»óµ¿¸Æ Áúȯ(10.2%, vs. 5.2% among those without disease; OR, 2.70; 95% CI, 2.08 to 3.51)
3. ½ÉºÎÀü(15.3%, vs. 5.6% among those without heart failure; OR 2.48; 95% CI, 1.62 to 3.79)
4. ½ÉÀåºÎÁ¤¸Æ(11.5%, vs. 5.6% among those without arrhythmia; OR, 1.95; 95% CI, 1.33 to 2.86)
5. ¸¸¼ºÆó¼â¼ºÆóÁúȯ(14.2%, vs. 5.6% among those without disease; OR, 2.96; 95% CI, 2.00 to 4.40)
6. ÇöÀç Èí¿¬(9.4%, vs. 5.6% among former smokers or nonsmokers; OR, 1.79; 95% CI, 1.29 to 2.47)
¾à¹°Ä¡·á¿Í »ç¸Á·ü°úÀÇ °ü·ÃÀ» ºÐ¼®ÇÑ °á°ú, ACE inhibitors (2.1% vs. 6.1%; OR, 0.33; 95% CI, 0.20 to 0.54) »ç¿ëÀ̳ª, ARB(6.8% vs. 5.7%; OR, 1.23; 95% CI, 0.87 to 1.74) ¾à¹°Ä¡·á´Â º´¿ø³»¿¡¼ »ç¸ÁÀ§ÇèÀ» Áõ°¡½ÃÅ°´Â °Í°ú °ü·ÃÀÌ ¾ø´Â °ÍÀ¸·Î ³ªÅ¸³µ´Ù. [¿ø¹®º¸±â]
COVID-19: ÁßÁõ ¼ºÀÎȯÀÚ ICU ÆÐÇ÷Áõ °¡À̵å¶óÀÎ
ÁßÁõ±Þ¼ºÈ£Èí±âÁõÈıºÀ» ¾ß±âÇÏ´Â SARS-CoV-2´Â Àü¼¼°èÀûÀ¸·Î ±Þ¼ÓÇÏ°Ô È®»êµÇ°í ÀÖÀ¸¸ç ¼ö¸¹Àº »ç¶÷µéÀÇ »ý¸íÀ» À§ÇùÇÏ°í ÀÖ´Ù. À̵éÀ» µ¹º¸´Â º¸°ÇÀÇ·áÀεé°ú ÀÓ»óÀǻ縦 À§ÇÑ ±ä±ÞÇÑ °¡À̵å¶óÀÎ °³¹ßÀÌ ÇÊ¿äÇÏ´Ù. COVID-19·Î ÀÎÇÑ ÆÐÇ÷Áõ °ü¸® ÁöħÀ» À§ÇØ ±¸¼ºµÈ ÆгÎÀº 54°³ÀÇ Áø¼ú¹®À» ¸¸µé¾ú°í ÀÌÁß¿¡¼ 4°¡Áö º£½ºÆ® ½Ç¹«°¡À̵å¶óÀΰú 9°¡Áö °·ÂÇÑ ±Ç°í»çÇ×°ú, 35°¡Áö Áõ°Å°¡ ºÎÁ·ÇÑ Á¦¾ÈµéÀº ¹ßÇ¥Çß´Ù. [´õº¸±â]
Ç¥ 5) Coronavirus disease (COVID-19) ±¹³» ¹× ±¹¿Ü COVID -19 ÃֽŠÁ¤º¸ ¹Ù·Î°¡±â
Ç¥ 6) Coronavirus disease (COVID-19) ÃֽŠÇмúÁ¤º¸ »çÀÌÆ® ¹Ù·Î°¡±â
References
Çѱ¹ : Á߾ӹ濪´ëÃ¥º»ºÎ Á¤·Êºê¸®ÇÎ º¸µµÀÚ·á
WHO, Coronavirus (COVID-19) Situation reports
Áß±¹ : ±¹°¡À§»ý°Ç°À§¿øȸ ȨÆäÀÌÁö
ÀÌÅ»¸®¾Æ : º¸°ÇºÎ ȨÆäÀÌÁö
ÀϺ» : ÈÄ»ý³ëµ¿¼º º¸µµÀÚ·á
¿µ±¹ : Á¤ºÎ»çÀÌÆ®
À̶õ · ¹Ì±¹ : Coronavirus COVID-19 Global Cases by Johns Hopkins CSSE
ÀÇ°úÇבּ¸Á¤º¸¼¾ÅÍ Á¦°ø